Ipecac Syrup

Quick links to important sections

Ipecac Syrup

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ipecac Syrup

What is Ipecac Syrup? Defining the Emetic Agent

Property Description
Active Ingredient Ipecac alkaloids (Emetine, Cephaeline)
Form Syrup, Oral solution
Pharmacological Class Emetic, Expectorant (secondary)
General Purpose To induce vomiting (emesis)
Origin Natural product (Ipecacuanha root)

Ipecac Syrup is a liquid pharmaceutical preparation historically classified as an emetic agent, meaning its primary function is to cause induced vomiting (emesis). This medicine, historically standardized under the United States Pharmacopeia (USP), is categorized by its ability to provoke the rapid expulsion of stomach contents via the oral route of administration. The primary purpose of this preparation is directly related to its classification, historically serving as a method for the rapid clearance of the digestive system.

What Type of Medicine is Ipecac Syrup?

Ipecac Syrup is classified primarily as a potent emetic, while its active components also possess a secondary function as an expectorant, aiding in the fluidification and clearance of mucus from the respiratory system. The preparation is a single product derived from natural product sources, specifically the ground roots and rhizomes of the South American plant, Carapichea ipecacuanha (Ipecacuanha root). The roots contain the active compounds which were used in medicine historically for their ability to cause emesis. This historical use is clinically recognized for its reliability in producing a rapid gastric response when needed for acute ingestion scenarios.

Composition and Source: The Alkaloid Core

The efficacy of Ipecac Syrup is rooted in its content of Ipecac alkaloids, predominantly Emetine and Cephaeline, extracted from the Ipecacuanha root. This formulation is presented as an oral solution or a syrup, which suspends the active alkaloids in a palatable liquid vehicle, typically a sugar-based base, facilitating ingestion. The dual mechanism of action—where Emetine primarily targets the central nervous system’s vomiting center and Cephaeline causes a significant peripheral component via local gastric irritation—involves the distinct roles of the compounds. Ipecac is historically significant in toxicology for its potent emetic properties.

Regulatory References

  1. Ipecac - StatPearls - NCBI Bookshelf

What side effects are possible with Ipecac Syrup?

Possible side effects and safety information

The safety profile of Ipecac Syrup is defined by its primary action and the potential for systemic toxicity from its alkaloid content, primarily Emetine, which is associated with serious outcomes when the product is misused or overused. Adverse reactions are often grouped by the organ systems they affect, according to official regulatory classification.


Adverse Reaction Classification and Scope

Category Documented Characteristics
System-Organ Classes Effects documented in Cardiac Disorders, Musculoskeletal and Connective Tissue Disorders, Nervous System Disorders, and Gastrointestinal Disorders (including profuse vomiting and diarrhea).
Serious Adverse Reactions Officially listed severe outcomes include Cardiomyopathy (damage to the heart muscle), Severe Cardiac Arrhythmias, and Irreversible Skeletal Muscle Damage (Myopathy). Fatal outcomes have been documented in cases of prolonged exposure or abuse.
Duration-Related Risk The most serious cardiotoxicity and myopathy are explicitly associated with chronic, repeated, or excessive use, rather than acute, single-dose therapeutic administration.

Safety Restrictions and Special Populations

Regulatory documentation includes several safety-related restrictions concerning the product's use. It is officially contraindicated for use in patients who are unconscious, semiconscious, or have a depressed gag reflex, primarily due to the severe risk of aspirating stomach contents into the lungs. Furthermore, the product is contraindicated following the ingestion of corrosive agents (such as strong acids or alkalies) or petroleum distillates (hydrocarbons), as vomiting in these cases may cause additional injury. Official safety warnings exist that specifically discourage use in infants.


The overall safety profile emphasizes that the most severe risks, including fatal myocardial necrosis, are classified as serious adverse reactions associated with the systemic accumulation of alkaloids following misuse or abuse.

Overdose and Emergency Response

Ipecac Syrup overdose is officially documented by severe manifestations resulting from prolonged or repeated exposure to its alkaloids, primarily Emetine. Clinically, overdose may present with protracted gastrointestinal effects, including persistent nausea or vomiting lasting longer than 30 minutes, severe diarrhea, stomach cramps, and the presence of bloody stools or vomitus.

The most serious outcomes are linked to cardiotoxicity, where systemic absorption of Emetine can lead to severe EKG abnormalities, hypotension, and arrhythmias. These effects signal a risk for severe myocardial damage, including myocarditis, heart failure, and potentially fatal cardiomyopathy. Documented physical complications from forceful emesis include Mallory-Weiss tears and aspiration pneumonitis.

Regulatory authorities state that immediate medical attention must be sought upon suspected overdose or if the expected emetic action fails after a second dose, which suggests high systemic alkaloid absorption. For management, the drug must be discontinued, and care is limited to symptomatic and supportive treatment, as no specific antidote exists for the documented cardiotoxic effects. Chronic toxicity, particularly from misuse, is a specific concern noted in official documentation due to its association with severe and fatal cardiac outcomes.

Therapeutic Uses of Ipecac Syrup

Main Therapeutic Domains and Benefits

The core therapeutic application of Ipecac Syrup is applied across domains where additional symptomatic support is needed in situations involving acute, distressing symptoms. This application is associated with conditions involving acute or disruptive episodes.

Symptomatic Discomfort and Acute Episodes

The historical therapeutic use of Ipecac Syrup is applied in clinical settings that involve acute or unstable symptom patterns in situations involving certain distressing symptoms. This function is generally used to help address symptoms related to heightened physiological activity. The product is relevant in contexts marked by increased discomfort or tension, such as in cases involving certain categories of acute or disruptive episodes.

Addressing Functional Strain from Symptoms

This treatment is applied when conditions produce significant symptomatic burden and symptoms interfere with daily comfort. The overall benefit helps to ease the overall symptom load and may assist with maintaining functional stability during the critical phase when symptoms may intensify temporarily, providing supportive symptom management. This makes the product relevant in contexts involving heightened systemic burden.

Applicable in cases involving symptoms that interfere with daily functioning

The conditions where this product is relevant are generally characterized by periods of heightened symptoms, often involving episodic or fluctuating manifestations.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Eligibility for Ipecac Syrup is strictly defined by regulatory bodies to mitigate the inherent risks associated with induced vomiting. The medicine is documented for use in adults, teenagers, and children one year of age and older under appropriate guidance.


Absolute Contraindications

Use is explicitly prohibited in any person who is unconscious or has a compromised airway protective reflex, such as an absent gag reflex, due to the high risk of pulmonary aspiration. The medicine is also strictly contraindicated for individuals misusing it to cause vomiting for the purpose of weight loss, due to the documented risk of serious cardiotoxicity.

Restricted or Conditional Use

Regulatory documents state that use is ordinarily not recommended after the ingestion of certain substances, including corrosive agents (acids or alkalies) or petroleum distillates (e.g., gasoline), as vomiting exacerbates injury and increases aspiration risk.

For infants six months of age or younger, administration is only permitted under the direction of a physician. Use requires caution in patients with pre-existing heart disease. For pregnant individuals, the drug is assigned Pregnancy Category C status, restricting use to situations where the benefit clearly outweighs the potential risk.

What should I know about interactions with other medicines?

The official regulatory profile for Ipecac Syrup is defined by interactions that create physiologic risk or cause functional antagonism, rather than typical metabolic drug-drug interactions. The interaction data is primarily based on constraints and warnings documented by governmental health authorities.


Classification Official Regulatory Interaction Information
Contraindicated Combinations The co-ingestion of corrosives (e.g., strong acids, alkalies) and petroleum distillates (e.g., kerosene, gasoline) is a contraindicated combination. This is due to the severe risks of secondary injury to the esophagus and pulmonary aspiration when vomiting is induced. Furthermore, co-ingestion of substances that cause CNS depression or seizures is prohibited due to the risk of aspiration associated with a compromised protective reflex.
Functional Antagonism Co-administration with antiemetics may result in functional antagonism, diminishing the intended therapeutic emetic effect. Activated Charcoal causes a physical adsorption interaction, binding to and inactivating the syrup's active alkaloids, which prevents emesis.

Timing-Separation Rules and Exposure Risk:

  • Timing Constraint: Ipecac administration may delay or reduce the effectiveness of subsequent treatments, including Oral Antidotes, Activated Charcoal, and Whole-Bowel Irrigation. These procedures are subject to a timing-separation rule and should be administered only after emesis has stopped.
  • Food/Beverage Restrictions: Restriction applies to co-administration with Milk or Milk Products and Carbonated Beverages, which are documented to interfere with emetic effectiveness or cause abdominal distention.
  • Systemic Exposure: Failure of the primary emetic function is an exposure constraint, as it leads to increased systemic absorption and elevated exposure to the alkaloid Emetine.

Mechanism of Action

Dual-Route Activation of the Emesis Center

Ipecac Syrup's effect is driven by the combined, dual action of its alkaloids, Emetine and Cephaeline, which directly target key pathways that control the body's emetic response. The drug initiates a robust physiological response by stimulating the central and peripheral nervous systems simultaneously. This dual mechanism covers the direct chemical activation of the Chemoreceptor Trigger Zone (CTZ) in the brainstem (central action) and the local chemical irritation of gastric sensory receptors in the stomach lining (peripheral action). These two pathways converge to send a high-intensity signal to the brain's Vomiting Center, coordinating the involuntary expulsion of gastric contents.

Vagal Reflex and Secretory Modulation

Secondary to the primary action, the alkaloids influence the Vagus nerve reflex. The stimulation of Vagal pathways at low concentrations causes a subsequent increase in the output and fluidification of secretions from bronchial secretory cells. This adjustment in glandular secretion is a consequence of the drug's action on autonomic pathways, which alters the fluid output within the respiratory tract.

Constraints on Central Pathway Integrity

The central mechanism is subject to pharmacological constraints. The effectiveness of the CTZ stimulation pathway is weakened or overridden if antagonistic substances or CNS depressants are present, as these agents physically block or diminish the activity of the receptors that the Ipecac alkaloids are intended to activate.

Dosage and Administration Information

Ipecac Syrup is a standardized oral solution for use as a single-event emetic intervention. Administration is strictly conditioned on consulting a qualified health professional—such as a physician or Poison Control Center—immediately before use.


Official Administration Guidelines

The following dosing and procedural steps reflect the medicine’s labeled instructions:

Category Official Administration Parameter
Route & Form Oral administration of the Syrup (USP) formulation only. The Fluidextract or Tincture preparations must not be used.
Standard Dosing Adults and Teenagers (12+ years): The typical dose is 15 to 30 mL. Children (1 to 12 years): The typical dose is 15 mL.
Frequency & Limit A single dose is given. The dose may be repeated one time only after 20 to 30 minutes if the initial administration does not produce the expected effect.

Procedural Conditions

The administration protocol includes specific requirements for fluid intake and duration. The dose must be followed immediately by drinking a full glass of clear liquid, typically water (approx. 240 mL for adults), to ensure proper action. Milk, milk products, or carbonated beverages must not be used, as they may interfere with the intended response.

Administration in infants under six months of age is restricted and must be performed only under the supervision of a physician. The regimen limits use to two total doses. If the intended effect does not occur after the second administration, the patient is required to seek immediate professional medical attention.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ipecac Syrup

1. Research Evidence for Acute Toxic Ingestion

Ipecac Syrup was evaluated in research exploring its historical application in acute situations involving the possible ingestion of toxic substances, also known as poisoning. The research base in this area primarily consists of controlled volunteer studies and observational reports. Controlled studies examined how much of a marker substance could be recovered from the stomach and how quickly vomiting occurred (emesis) in healthy adults. Observational reports, on the other hand, studies monitored the short-term experience of patients in emergency or home settings who received the syrup compared to those who did not.

Studies reported patterns where Ipecac Syrup was associated with the induction of vomiting in the populations studied. Research explored measurements related to the amount of substance recovered from the stomach, with findings indicating that the amount recovered varied across studies depending on the timing of administration. In some studies, data show patterns related to changes in the plasma concentration of the ingested substance. This evidence contributes to understanding the observed physiological response in the immediate aftermath of a toxic event.

2. Research on Clinical Outcomes and Comparative Trials

Studies also explored the relationship between Ipecac administration and broader clinical outcomes, such as hospital admission rates and the overall condition of patients following the acute event. The findings were mixed when observational reports assessed whether Ipecac Syrup use was associated with specific changes in patient outcomes, such as hospital duration or the occurrence of serious clinical events. Available research describes group patterns, not personal outcomes, and data show patterns related to the variability of results.

3. What Is Still Uncertain About the Research for Ipecac Syrup

Authoritative reviews and position papers have highlighted key areas of uncertainty within the research base. The certainty remains low regarding whether Ipecac Syrup use is associated with changes in major patient outcomes, such as survival or reduced overall illness severity in acute toxic ingestion. One of the research limitation frames is the limited number of Randomized Controlled Trials (RCTs) designed to measure definitive clinical benefit. Furthermore, comparative evidence is lacking in large-scale studies that definitively show Ipecac is superior to or even as helpful as alternative methods of gastric decontamination.

Key Studies & References

  1. Ipecac - StatPearls [Internet] - NCBI Bookshelf (NIH)
  2. Position Statement: Ipecac Syrup - The American Academy of Clinical Toxicology (1997)

Frequently Asked Questions (FAQ)

Common questions about Ipecac Syrup (FAQ)

Q: How quickly does Ipecac Syrup usually make someone vomit?

Official information indicates that the product is intended to be effective in inducing vomiting (emesis). Studies and product information suggest that the onset of this effect typically occurs within 30 minutes after the syrup is administered.

Q: What happens if Ipecac Syrup is taken but does not cause vomiting?

If the intended effect does not occur, regulatory warnings exist about the potential for increased systemic exposure to the alkaloid Emetine, which can accumulate in the body. Regulatory documents indicate the need to seek immediate professional medical attention if the expected effect does not occur.

Q: Is Ipecac Syrup the same as activated charcoal?

No, regulatory information describes Ipecac Syrup as an emetic agent, meaning its function is to cause induced vomiting. Activated Charcoal is an adsorbent material that physically binds to substances in the stomach. Official information describes that the physical binding action of Activated Charcoal can diminish the effectiveness of the Ipecac alkaloids.

Q: Is it true that Ipecac Syrup is not recommended by poison control centers anymore?

Official position statements from leading medical and advisory bodies, including the American Academy of Pediatrics, have advised against the routine use of Ipecac Syrup for the home treatment of ingestions. This change in recommendation is based on a review of current clinical evidence.

Q: What official warnings are associated with Ipecac Syrup use?

Official warnings, as detailed in the Code of Federal Regulations, state that the syrup should be used only for emergency purposes to cause vomiting. Use is officially contraindicated for individuals who are unconscious or after the ingestion of certain substances, such as corrosive agents (strong acids or bases) or petroleum distillates.

Q: Why do official sources state that Ipecac Syrup can be dangerous if misused?

Official documents describe that chronic, repeated, or excessive use (misuse) may lead to the systemic accumulation of the alkaloid Emetine. This accumulation is associated with serious adverse reactions, including cardiotoxicity (damage to the heart muscle) and irreversible skeletal muscle damage.

Q: Why is the drug Ipecac Syrup no longer used in many clinical settings?

Authoritative reviews have cited insufficient evidence from rigorous clinical studies showing that the syrup improves patient outcomes in acute toxic ingestion. Official concerns were also noted that its use may delay the administration of other treatments that are considered more effective in a clinical setting.

Q: Is Ipecac Syrup still available to buy in pharmacies?

While historically available over-the-counter, regulatory and commercial information indicates that manufacturing of Ipecac Syrup has been discontinued by the last US producers. As a result, the product’s widespread availability has been significantly reduced, particularly in the United States.

Q: Why was Ipecac Syrup commonly kept in homes in the past?

Regulatory documents historically permitted the drug for over-the-counter sale for quick first-aid use in the home following accidental poisoning. This was supported by recommendations from medical bodies at the time who encouraged immediate availability in case of emergency.

Q: Are there different strengths of Ipecac Syrup?

Official information and patient guidance strictly distinguish the Ipecac Syrup formulation from other preparations, such as the Ipecac Fluidextract or Tincture. Official warnings state that only the syrup contains the proper strength for use as a regulated emetic.

Q: Can Ipecac Syrup be used for general nausea or an upset stomach?

The product is officially classified and labeled as an emetic agent for the specific purpose of inducing vomiting in cases of poisoning. Its regulatory profile does not describe or support its use for treating general nausea, indigestion, or an upset stomach.

Q: How long does the vomiting effect from Ipecac Syrup last?

Pharmacokinetic data from studies on Ipecac Syrup indicate that, while it causes rapid emesis, the effect and associated symptoms may last up to approximately one hour in some studied cases.

Q: Is there any research on Ipecac Syrup's effect on drug absorption?

Yes, studies have examined the effect of the syrup on the mean plasma concentrations of certain ingested substances. Some findings have indicated a reduction in the bioavailability (the body's ability to absorb the substance) if the syrup is administered soon after ingestion.

Q: Has Ipecac Syrup ever been studied for uses other than poisoning?

Regulatory classification acknowledges a secondary function as an expectorant, which is a historical use of the plant-derived compounds. However, the product's primary clinical indication and regulatory focus is limited to its use as an emetic agent in cases of acute poisoning.

Q: What ingredients are listed on the official label of Ipecac Syrup?

Official formulations require the presence of the active ingredients, Ipecac alkaloids (Emetine and Cephaeline). It is typically prepared as a syrup with inactive ingredients—such as sucrose, water, and alcohol—to create a palatable liquid vehicle.

Q: Does Ipecac Syrup expire, and does it become less effective after a certain time?

Regulatory guidelines require drugs to have an expiration date to ensure their strength and purity over time. However, some studies have suggested that Ipecac Syrup may retain its emetic efficacy even several years past its labeled expiration date.

Q: Is Ipecac Syrup known by any other names?

Yes, official drug databases and sources often list alternative names for the product, including the simple terms Ipecac and Ipecacuanha (the name of the source plant).

Q: Does the use of Ipecac Syrup affect blood pressure?

Adverse event reporting documents have included instances of cardiovascular side effects. These reports include decreased cardiac output and hypotension (low blood pressure) associated with its use.

Q: Can Ipecac Syrup cause changes in heart rhythm?

Yes, documented adverse reactions include cardiovascular effects. These can involve changes in heart function such as tachycardia (a fast heart rate), palpitations, and various cardiac arrhythmias (irregular heart rhythms).

Q: Is Ipecac Syrup addictive?

While not generally classified as an addictive substance, regulatory information highlights a known risk of chronic ipecac abuse. This potential for compulsive ingestion is primarily seen in certain high-risk populations, particularly those with eating disorders.

Q: What does the FDA say about the safety profile of Ipecac Syrup?

The FDA's regulatory history includes approving its initial non-prescription sale for emergency use. However, later regulatory panels recommended the revocation of its over-the-counter status due to documented concerns over potential abuse and a lack of confirmed clinical benefit in certain scenarios.

Q: Is there a maximum amount of Ipecac Syrup that official documents describe?

Official dosage guidelines state that if the first dose does not produce emesis, the dose may be repeated one time only. No more than two total doses should be administered, according to these guidelines.

Q: Do official patient information leaflets mention long-term effects of Ipecac Syrup use?

Yes, official safety information explicitly lists serious adverse outcomes like cardiomyopathy and irreversible skeletal muscle damage. These effects are classified as risks associated with chronic, repeated, or excessive use (long-term misuse).

Q: Why is the availability of Ipecac Syrup restricted in some regions?

Availability has been impacted by evidence from medical organizations recommending against routine use in the home setting. This led the FDA to request manufacturers to voluntarily cease marketing the product for over-the-counter, at-home use.

Q: Does Ipecac Syrup have sedative effects?

Nervous system side effects documented in adverse event reporting include effects such as drowsiness and lethargy.

Q: What distinguishes the liquid form of Ipecac Syrup from other preparations of ipecac?

Official warnings emphasize that the Syrup is the only preparation of the correct strength for intended use. This distinguishes it from other forms like the Fluidextract or Tincture, which are significantly more potent and have been associated with serious side effects.

Q: Is it possible to be allergic to Ipecac Syrup?

While the product is not specifically classified with a dedicated allergy alert, regulatory guidance requires manufacturers to label for potential hypersensitivity in relevant cases. General adverse event documents also caution on its use, as with most medications.

Q: What kind of studies have been performed to assess Ipecac Syrup’s effectiveness?

The research evidence base is described as primarily consisting of controlled volunteer studies and observational reports. These studies typically focused on examining the rates of substance recovery from the stomach and the time it took to induce vomiting.

Q: Does Ipecac Syrup affect the liver or kidneys?

Chronic abuse of the product has been associated with reports of hepatic (liver) and renal (kidney) dysfunction.

Q: What should a patient expect regarding the taste or consistency of Ipecac Syrup?

The formulation is officially described as a syrup and an oral solution. It is typically prepared with a sugar-based vehicle to make the preparation more palatable for ingestion.

Q: Are there any specific storage requirements for Ipecac Syrup mentioned in the documentation?

Regulatory guidance and patient information state that the product must be stored at room temperature in a closed container. Documentation also explicitly advises to protect the syrup from freezing.

Q: Why is it important to contact a poison control center before using Ipecac Syrup?

The official FDA warning requires the user to call a physician or Poison Control Center immediately for advice before use. This step is mandated to ensure that the specific type of poisoning event is appropriate for treatment by induced vomiting.

How should Ipecac Syrup be stored and disposed of?

Storage and Handling Requirements

Ipecac Syrup must be stored at room temperature in a closed container. Regulatory guidance mandates protection from environmental extremes, specifically advising to keep from freezing and away from heat, moisture, and direct light.

Child Safety: The medication must always be stored out of the reach of children.

Stability and Disposal Rules

To ensure product integrity, do not keep outdated medicine or medicine that is no longer needed. Opened bottles may allow for evaporation over time, so they should be replaced.

Official Disposal: Unused or expired Ipecac Syrup must be disposed of properly and safely. Official-source patient guidance often recommends flushing the syrup down the toilet to safely remove it from the home environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ipecac Syrup found in:

A-Z Index: